SafeNest unveils ‘One Safe Place,' with plans to have it open by Oct. 30
LAS VEGAS (KLAS) — SafeNest unveiled a first-of-its-kind centralized hub for victims of domestic and sexual violence on Thursday, with plans to have it ready in about six months.
Clark County ranks No. 1 in the country for domestic violence homicides. Liz Ortenburger, CEO of SafeNest, said she's glad to be a part of this new initiative and bring awareness to the growing number of victims in the area.
'There had to be some change. I'm happy it's this and I'm glad the state chose to invest,' Ortenburger said.
Thursday's unveiling of 'One Safe Place' featured the ceremonial passing of the SafeNest purple key to symbolize the new campus.
The new space will provide over 500 individual survivor-focused services, including legal response, advocacy response, counseling, crisis response and housing services.
Victims can also get help with WIC, food stamps and social services. Lisa Lopez, a domestic violence survivor and now SafeNest board member, said having all of SafeNest's resources under one roof will help reach more victims.
'It's very hard when you have children, and you have jobs. It's long days of driving from place to place, waiting in long lines and waiting for appointments. So having all of this under one roof will significantly change a survivor's outcome to a positive one,' Lopez said.
The new hub is set to open Oct. 30. The new building must still be purchased and renovated with an estimated cost of $17 million. The state of Nevada is providing $9 million of the funding. SafeNest plans to launch a campaign to raise the rest.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Luminar Technologies, Inc. (LAZR) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Luminar Technologies, Inc. (LAZR) closed the latest trading day at $3.27, indicating a -5.49% change from the previous session's end. The stock's change was less than the S&P 500's daily loss of 0.27%. Shares of the company witnessed a loss of 23.62% over the previous month, trailing the performance of the Auto-Tires-Trucks sector with its gain of 5.86%, and the S&P 500's gain of 6.9%. Analysts and investors alike will be keeping a close eye on the performance of Luminar Technologies, Inc. in its upcoming earnings disclosure. On that day, Luminar Technologies, Inc. is projected to report earnings of -$1.19 per share, which would represent year-over-year growth of 55.93%. Meanwhile, our latest consensus estimate is calling for revenue of $16.72 million, up 1.64% from the prior-year quarter. For the full year, the Zacks Consensus Estimates are projecting earnings of -$4.29 per share and revenue of $86.64 million, which would represent changes of +53.57% and +14.91%, respectively, from the prior year. Investors should also pay attention to any latest changes in analyst estimates for Luminar Technologies, Inc. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 21.36% higher within the past month. Luminar Technologies, Inc. is currently sporting a Zacks Rank of #2 (Buy). The Automotive - Original Equipment industry is part of the Auto-Tires-Trucks sector. This industry currently has a Zacks Industry Rank of 131, which puts it in the bottom 47% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Luminar Technologies, Inc. (LAZR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
43 minutes ago
- Yahoo
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a biotechnology laboratory. The candidate supported monthly dosing with the longest half-life of any known amylin analog, 19 days. MET-233i had no safety indications and was well tolerated. The trial included 80 overweight or obese participants, with individual cases resulting in weight loss of up to 10.2%. MET-233i displayed high tolerability and dose-linear pharmacokinetics when tested in both single and multiple ascending dose formats. The majority of adverse gastrointestinal events occurred in the first week and were mild and dose-dependent. According to preliminary findings, it might make it practical to use its fully-biased GLP-1 RA candidate, MET-097i, in the first monthly GLP-1 + amylin combination therapy. Topline results from combination trials and an ongoing monotherapy study with MET-097i are anticipated in late 2025. Metsera, Inc. (NASDAQ:MTSR)'s HALO™ peptide stabilization platform supports the program. Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical business focused on developing new treatments for obesity and metabolic diseases. It is one of the stocks with the biggest upside. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
‘Handle With Care' statewide trauma-sensitive program to support children with help of law enforcement, educators
KANSAS, Ill. (WCIA) — Law enforcement officers across Illinois are connecting with educators to support children after they may have experienced a traumatic or stressful event outside of the classroom. Doug Cochran with the Kansas Police Department serves as the law enforcement liaison to bring 'Handle With Care' to police departments and schools across the state. The goal is to support kids and provide extra support when they go to school after challenging, traumatic events. WATCH the above video for more details with Cochran and Ambrosia Branson, the project coordinator. If you're a school district or law enforcement officer interested in using Handle With Care, reach out to Cochran at 217-712-0172 or KPDdcochran22@ Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
